Poor
Needs Revision
Patient Risk:
Moderate
Summary
The AI response makes many general drug/efficacy and safety claims, but the provided FDA label excerpts only address boxed-warning topics (CV thrombotic events, GI bleeding) and a CABG contraindication. Most statements cannot be verified against the supplied label text, and several safety claims are only partially supported (lacking specificity/quantification) relative to the provided warnings.
Category Scores
Accurate Statements
Celebrex carries risks including an increased risk of heart attack.
Supported generally by Label 5.1 Cardiovascular Thrombotic Events stating increased risk of serious cardiovascular thrombotic events including myocardial infarction (MI).
Celebrex carries risks including an increased risk of stroke.
Supported generally by Label 5.1 Cardiovascular Thrombotic Events stating increased risk of serious cardiovascular thrombotic events including stroke.
Celebrex carries risks including an increased risk of gastrointestinal bleeding.
Supported generally by Label 5.2 Gastrointestinal Bleeding, Ulceration, and Perforation stating NSAIDs including celecoxib cause serious GI adverse events including bleeding.
Unsupported Statements
Celecoxib (marketed as Celebrex) is a nonsteroidal anti-inflammatory drug (NSAID).
Not supported or contradicted by the provided label excerpts (which cover warnings/precautions and contraindications only).
Celecoxib (Celebrex) is used to treat pain and inflammation associated with osteoarthritis.
No indication/usage information is included in the provided label excerpts.
Celecoxib (Celebrex) is used to treat pain and inflammation associated with rheumatoid arthritis.
No indication/usage information is included in the provided label excerpts.
Celecoxib (Celebrex) is used to treat pain and inflammation associated with ankylosing spondylitis.
No indication/usage information is included in the provided label excerpts.
Celecoxib (Celebrex) is prescribed for acute pain in adults.
No indication/usage information is included in the provided label excerpts.
Celecoxib (Celebrex) is prescribed for menstrual pain.
No indication/usage information is included in the provided label excerpts.
Celebrex is selective COX-2 inhibitor.
Mechanism details are not provided in the supplied label excerpts.
Celebrex works by blocking cyclooxygenase-2 (COX-2).
Mechanism details are not provided in the supplied label excerpts.
COX-2 is involved in the production of prostaglandins.
Mechanism details are not provided in the supplied label excerpts.
Prostaglandins contribute to inflammation, pain, and fever.
Mechanism details are not provided in the supplied label excerpts.
By inhibiting COX-2, celecoxib reduces inflammation, pain, and fever symptoms.
Mechanism details are not provided in the supplied label excerpts.
Clinical trials have demonstrated celecoxib's efficacy in managing pain and inflammation in osteoarthritis.
No efficacy/clinical trial outcome information is included in the provided label excerpts.
Clinical trials have demonstrated celecoxib's efficacy in managing pain and inflammation in rheumatoid arthritis.
No efficacy/clinical trial outcome information is included in the provided label excerpts.
Clinical trials have demonstrated celecoxib's efficacy in managing acute pain.
No efficacy/clinical trial outcome information is included in the provided label excerpts.
Celebrex's selective inhibition of COX-2 was intended to reduce certain gastrointestinal side effects associated with older NSAIDs.
No such rationale/mechanism-for-safety statement is included in the provided label excerpts.
Common side effects of Celebrex can include abdominal pain.
No adverse reaction (side effect) list is included in the provided label excerpts.
Common side effects of Celebrex can include diarrhea.
No adverse reaction (side effect) list is included in the provided label excerpts.
Common side effects of Celebrex can include indigestion.
No adverse reaction (side effect) list is included in the provided label excerpts.
Common side effects of Celebrex can include gas.
No adverse reaction (side effect) list is included in the provided label excerpts.
Common side effects of Celebrex can include headache.
No adverse reaction (side effect) list is included in the provided label excerpts.
Celecoxib (Celebrex) is prescribed to reduce the number of adenomatous colorectal polyps in familial adenomatous polyposis (FAP).
No indication/usage information is included in the provided label excerpts.
Celecoxib (Celebrex) is also known by its generic name, celecoxib.
Label excerpt does not address naming/generic availability; also the statement is internally odd (brand and generic are the same active ingredient name). Not verifiable against provided excerpts.
The original patent for Celebrex has expired.
No patent/market exclusivity information is included in the provided label excerpts.
The expired patent allows for availability of generic versions of celecoxib.
No patent/market exclusivity information is included in the provided label excerpts.
Some NSAIDs are non-selective COX inhibitors that block both COX-1 and COX-2 enzymes.
No drug-class mechanistic comparison is included in the provided label excerpts.
Examples of non-selective COX inhibitors include ibuprofen and naproxen.
Not supported by the provided label excerpts (though naproxen/ibuprofen appear in PRECISION trial text, that is not the same as a general statement of class inhibition).
Generic versions of celecoxib are available.
No generic availability information is included in the provided label excerpts.
Generic celecoxib is typically bioequivalent to the brand-name drug.
No bioequivalence information is included in the provided label excerpts.
Bioequivalent generics are expected to have the same effects and safety profile.
No bioequivalence/safety equivalence language is included in the provided label excerpts.
Generic options of celecoxib are often less expensive than brand-name Celebrex.
No pricing information is included in the provided label excerpts.
Pfizer Inc. is the original manufacturer of Celebrex.
No manufacturer information is included in the provided label excerpts.
Brand-name Celebrex is generally more expensive than its generic counterpart, celecoxib.
No pricing information is included in the provided label excerpts.
Contradictions
Important Omissions
CABG-related contraindication statement (CELEBREX contraindicated in the setting of CABG surgery) is not mentioned.
Importance:
High
Within boxed-warning topics, the label includes specific guidance such as using the lowest effective dose for the shortest duration possible, and patient monitoring/alertness for CV and GI events; the AI response does not include these risk-minimization/monitoring recommendations.
Importance:
Moderate
Label-specific nuance about aspirin not mitigating CV thrombotic risk and increased risk of serious GI events with concurrent aspirin is not addressed.
Importance:
Moderate
The label’s GI bleeding timing/context (can occur at any time; only one in five symptomatic; approximate incidence over 3–6 months and one year) is omitted.
Importance:
Low
The AI’s safety/side-effect section does not distinguish boxed-warning serious risks from non-serious adverse reactions, and does not align with the label’s provided excerpts (no adverse reaction list supplied).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims are unsupported because the supplied label excerpts do not contain the relevant sections (indications, dosing/administration, adverse reactions). While the AI correctly states broad boxed-warning risks of MI, stroke, and GI bleeding, it omits key label contraindication (CABG) and key boxed-warning risk-minimization guidance (lowest effective dose/shortest duration; monitoring and patient alertness).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
Most statements (indications, dosing, mechanism, adverse reactions, and market/patent claims) are not supported by the provided FDA label excerpts; key label safety elements (CABG contraindication and risk-minimization/monitoring language) are omitted.
Suggested Improvement
Restrict claims to what is present in the supplied label excerpts (boxed-warning CV thrombotic events, GI bleeding, and CABG contraindication), and add specific label-aligned contraindication and risk-minimization/monitoring statements. Remove unsupported general MOA/indication/side-effect and market/patent/bioequivalence assertions unless additional on-label label sections are provided for verification.